Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Alliance for Clinical Trials in Oncology
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
Massachusetts General Hospital
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Menarini Group
Sanofi